The 2024-2025 COVID vaccine reduces the risk of dying from COVID by roughly 80% and cuts hospitalizations by about 40%. Those numbers come from CDC estimates covering the first six months after vaccination, and they reveal an important pattern: the sicker you’d get without the shot, the more protection it offers.
Protection Against Severe Illness
The updated vaccine’s effectiveness scales with severity. Against hospitalization alone, it sits at 40%. But the numbers climb sharply from there. For people with healthy immune systems, effectiveness reaches 46% against needing supplemental oxygen, 49% against acute respiratory failure, 60% against ICU admission, and 79% against being put on a ventilator or dying. In practical terms, this means the vaccine is best understood as a guard against the worst outcomes rather than a guarantee you won’t end up in the hospital at all.
That 40% hospitalization figure held steady through roughly six months post-vaccination. This is lower than some earlier vaccine formulations achieved when they were well-matched to the circulating variant, but the virus has continued to evolve, and the gap between the vaccine target and the variants actually spreading plays a major role in overall effectiveness.
How Well It Matches Current Variants
The 2024-2025 vaccines were designed around the JN.1 lineage of Omicron. Since then, the virus has continued to shift. Subvariants like KP.3, KP.2.3, and LB.1 have emerged, and lab studies show these newer subvariants are highly evasive of antibodies generated by previous vaccine formulations. A key mutation, a single amino acid deletion in the spike protein, gives these subvariants a distinct profile compared to the original JN.1 target.
This mismatch helps explain why the vaccine’s effectiveness against hospitalization sits at 40% rather than something higher. Your immune system still recognizes the virus well enough to mount a strong defense when it matters most (preventing death and ICU stays), but the antibody response isn’t as precise a fit as it would be against the exact strain the vaccine was built around. This is a familiar pattern from flu vaccination, where partial matches still meaningfully reduce severe outcomes.
mRNA vs. Protein-Based Options
Two types of updated COVID vaccines are available for 2024-2025: the mRNA vaccines from Pfizer and Moderna, and a protein-based vaccine from Novavax. The CDC effectiveness data above reflects the mRNA vaccines, which make up the vast majority of doses given.
The Novavax protein-based option uses a more traditional technology. In animal studies, the 2024-2025 Novavax formula produced stronger neutralizing antibodies against JN.1 and its descendants (including KP.2, KP.3, and others) compared to the previous year’s version. However, no new clinical trial data in humans was submitted for this update. The FDA authorized it based on the totality of evidence from earlier clinical trials, combined with the animal immunogenicity data. If you prefer a non-mRNA option, the Novavax vaccine is a reasonable choice, though the real-world effectiveness data specifically tracks the mRNA shots.
Impact on Long COVID Risk
Early in the pandemic, about 10% of people who caught COVID went on to develop Long COVID, a collection of symptoms like fatigue, brain fog, and shortness of breath lasting weeks or months. Among vaccinated people, that risk has dropped to roughly 3.5%. Researchers analyzing the decline in Long COVID cases from the pre-Delta era through Omicron found that about 70% of the reduction was attributable to vaccination.
This is one of the vaccine’s less discussed but most meaningful benefits. Even if you’re not worried about a severe acute infection, vaccination substantially lowers the odds of the kind of lingering illness that can disrupt daily life for months.
Timing Your Dose
If you recently had COVID, the CDC recommends you still get vaccinated but suggests waiting about 3 months after your infection. This isn’t because the vaccine is less safe sooner. It’s because your body already has fresh antibodies from the infection, so waiting lets you stretch out the period of strong protection rather than stacking redundant immunity.
For everyone else, the straightforward advice is to get the updated dose when it’s available, particularly before periods of higher transmission or if you’re older, immunocompromised, or have chronic health conditions. The protection against the most severe outcomes holds for at least six months, which is the window the current data covers.
Putting the Numbers in Context
A 40% reduction in hospitalization may sound underwhelming compared to the 90%-plus efficacy the original vaccines showed in 2021. But those early numbers reflected a near-perfect match between vaccine and virus, measured at peak immunity just weeks after vaccination. The current figures represent a more realistic, durable picture: protection against a virus that has mutated significantly, measured over months rather than weeks.
The more important number is the 79% reduction in the worst outcomes, ventilation and death. For a vaccine given once a year with mild side effects for most people, that level of protection against the most catastrophic scenarios remains substantial. COVID continues to kill tens of thousands of people annually in the United States, predominantly among the unvaccinated and those who haven’t received an updated dose.